GSK secured U.S. Food and Drug Administration approval for depemokimab as an add‑on treatment for patients aged 12 and older with certain inflammatory asthma indications, the company announced. GSK projects peak sales potential in the multi‑billion dollar range and positioned the monoclonal antibody as part of its late‑cycle respiratory portfolio expansion. The approval followed submission of efficacy and safety data to regulators and is expected to trigger U.S. commercial launch planning. GSK said the label will support use as an add‑on in patients not controlled on standard inhaled therapies.